{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:11:21Z","timestamp":1761052281742,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 81300435","No.81170521"],"award-info":[{"award-number":["No. 81300435","No.81170521"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.bcmd.2016.04.007","type":"journal-article","created":{"date-parts":[[2016,4,22]],"date-time":"2016-04-22T09:54:10Z","timestamp":1461318850000},"page":"58-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["EphB4-VAV1 signaling pathway is associated with imatinib resistance in chronic myeloid leukemia cells"],"prefix":"10.1016","volume":"59","author":[{"given":"Jin-Fang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing-Feng","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bcmd.2016.04.007_bb0005","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1634\/theoncologist.5-5-405","article-title":"Molecular abnormalities in chronic myeloid leukemia: deregulation of cell growth and apoptosis","volume":"5","author":"Di Bacco","year":"2000","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.bcmd.2016.04.007_bb0010","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/cncr.25656","article-title":"Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors","volume":"117","author":"Jabbour","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.bcmd.2016.04.007_bb0015","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"IRIS investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2016.04.007_bb0020","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.bcmd.2016.04.007_bb0025","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.leukres.2010.04.016","article-title":"Chen ZS\u00b7BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review","volume":"34","author":"An","year":"2010","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.bcmd.2016.04.007_bb0030","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1586\/14737140.8.1.99","article-title":"Targeted therapy in chronic myeloid leukemia","volume":"8","author":"Jabbour","year":"2008","journal-title":"Expert. Rev. Anticancer. Ther."},{"issue":"12","key":"10.1016\/j.bcmd.2016.04.007_bb0035","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","article-title":"AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL","volume":"94","author":"Weisberg","year":"2006","journal-title":"Br. J.Cancer"},{"issue":"12","key":"10.1016\/j.bcmd.2016.04.007_bb0040","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bcmd.2016.04.007_bb0045","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/leu.2009.111","article-title":"Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia","volume":"23","author":"Giles","year":"2009","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.bcmd.2016.04.007_bb0050","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1182\/blood.V99.11.4122","article-title":"BCR-ABL-induced adhesion defects are tyrosine kinase-independent","volume":"99","author":"Wertheim","year":"2002","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.bcmd.2016.04.007_bb0055","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1158\/0008-5472.CAN-03-3656","article-title":"Effect of mutational inactivation of tyrosine kinase activity on BCR\/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors","volume":"64","author":"Wertheim","year":"2004","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bcmd.2016.04.007_bb0060","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/BF02983800","article-title":"Effects of the tyrosine kinase inhibitor imatinib mesylate on a Bcr-Abl-positive cell line: suppression of autonomous cell growth but no effect on decreased adhesive property and morphological changes","volume":"78","author":"Nishihara","year":"2003","journal-title":"Int. J. Hematol."},{"issue":"10","key":"10.1016\/j.bcmd.2016.04.007_bb0065","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/leu.2009.111","article-title":"Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia","volume":"23","author":"Giles","year":"2009","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bcmd.2016.04.007_bb0070","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0092-8674(01)00391-9","article-title":"Signaling downstream of Eph receptors and ephrin ligands","volume":"105","author":"Schmucker","year":"2001","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.bcmd.2016.04.007_bb0075","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bcmd.2016.04.007_bb0080","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s12032-009-9267-z","article-title":"The role of heterogeneous nuclear ribonucleoprotein K in the progression of chronic myeloid leukemia","volume":"27","author":"Du","year":"2010","journal-title":"Med. Oncol."},{"issue":"1","key":"10.1016\/j.bcmd.2016.04.007_bb0085","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/jemt.10177","article-title":"Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis","volume":"59","author":"Nakamoto","year":"2002","journal-title":"Microsc. Res. Tech."},{"issue":"3","key":"10.1016\/j.bcmd.2016.04.007_bb0090","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s10620-010-1346-7","article-title":"Over-expression of Ephb4 is associated with carcinogenesis of gastric cancer","volume":"56","author":"Li","year":"2011","journal-title":"Dig. Dis. Sci."},{"issue":"8","key":"10.1016\/j.bcmd.2016.04.007_bb0095","first-page":"815","article-title":"The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl\u2013Crk pathway","volume":"8","author":"Noren","year":"2006","journal-title":"Nat. Biol."},{"issue":"43","key":"10.1016\/j.bcmd.2016.04.007_bb0100","doi-asserted-by":"crossref","first-page":"32574","DOI":"10.1074\/jbc.M604338200","article-title":"The EphB4 receptor-tyrosine kinase promotes the migration of melanoma cells through rho-mediated actin cytoskeleton reorganization","volume":"281","author":"Yang","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.bcmd.2016.04.007_bb0105","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2174\/187152908786786241","article-title":"Rho-signaling pathways in chronic myelogenous leukemia. Cardiovasc Hematol disord drug targets","volume":"8","author":"Kuzelov\u00e1","year":"2008","journal-title":"Cardiovasc. Hematol. Disord. Drug Targets"},{"key":"10.1016\/j.bcmd.2016.04.007_bb0110","article-title":"Effects of a fluorescent myosin light chain phosphatase inhibitor on prostate cancer cells","volume":"20","author":"ScottGrindrod1","year":"2011","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bcmd.2016.04.007_bb0115","first-page":"1","article-title":"Vav1 in hematologic neoplasms, a mini review","volume":"2","author":"Oberley","year":"2012","journal-title":"Am. J. Blood Res."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616300432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616300432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:31:51Z","timestamp":1761049911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979616300432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":23,"alternative-id":["S1079979616300432"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.04.007","relation":{},"ISSN":["1079-9796"],"issn-type":[{"type":"print","value":"1079-9796"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EphB4-VAV1 signaling pathway is associated with imatinib resistance in chronic myeloid leukemia cells","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}